Research Analysts Offer Predictions for NTLA FY2026 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities research analysts at HC Wainwright cut their FY2026 earnings estimates for shares of Intellia Therapeutics in a note issued to investors on Friday, August 7th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($3.06) per share for the year, down from their previous forecast of ($3.00). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.18) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q3 2027 earnings at ($0.81) EPS and FY2027 earnings at ($3.12) EPS.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Wolfe Research lowered Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price for the company. in a report on Wednesday, July 15th. Wedbush increased their target price on shares of Intellia Therapeutics from $12.00 to $17.00 and gave the stock a “neutral” rating in a research note on Friday, July 10th. New Street Research set a $25.00 target price on Intellia Therapeutics in a research note on Monday, June 15th. Finally, Leerink Partners set a $35.00 price target on shares of Intellia Therapeutics in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, eight have given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $20.85.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $12.02 on Tuesday. The firm’s 50-day simple moving average is $13.61 and its two-hundred day simple moving average is $13.48. Intellia Therapeutics has a 52 week low of $7.95 and a 52 week high of $28.25. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of -3.58 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.80). The company had revenue of $7.66 million during the quarter, compared to analyst estimates of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.Intellia Therapeutics’s quarterly revenue was down 46.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.98) earnings per share.

Institutional Trading of Intellia Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Comerica Bank boosted its position in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares during the period. Headlands Technologies LLC purchased a new position in shares of Intellia Therapeutics in the second quarter worth about $26,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at about $30,000. Advisory Services Network LLC bought a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at about $33,000. Finally, Fifth Third Bancorp bought a new stake in shares of Intellia Therapeutics in the 1st quarter valued at about $38,000. 88.77% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the transaction, the executive vice president directly owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. This trade represents a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Michael P. Dube sold 2,641 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares of the company’s stock, valued at approximately $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.